Novo Nordisk CEO says buyers of $49 compounded Wegovy pill will be 'wasting' their money

Reuters

Feb 05

<a href="https://laohu8.com/S/NVO">Novo Nordisk</a> CEO says buyers of $49 compounded Wegovy pill will be 'wasting' their money

COPENHAGEN, Feb 5 (Reuters) - Novo Nordisk NOVOb.CO CEO Mike Doustdar on Thursday told analysts in a call that people taking a compounded copy of the drugmaker's Wegovy pill priced at $49 will be wasting their money as the compound will not be absorbed in their body.

(Reporting by Maggie Fick and Louise Rasmussen, editing by Terje Solsvik)

((Louisebreusch.rasmussen@tr.com; +45 21 27 97 79;))

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2609301536"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2609301536\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2609301536?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-05 22:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2609301536","market":"fut","top_or_hot":-1,"title":"Novo Nordisk CEO says buyers of $49 compounded Wegovy pill will be 'wasting' their money","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a> CEO says buyers of $49 compounded Wegovy pill will be 'wasting' their money</title></head><body><p><span>COPENHAGEN, Feb 5 (Reuters)</span><span> - </span>Novo Nordisk <span>NOVOb.CO</span> CEO Mike Doustdar on Thursday told analysts in a call that people taking a compounded copy of the drugmaker's Wegovy pill priced at $49 will be wasting their money as the compound will not be absorbed in their body. </p><p> (Reporting by Maggie Fick and Louise Rasmussen, editing by Terje Solsvik)</p><p> ((Louisebreusch.rasmussen@tr.com; +45 21 27 97 79;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novo Nordisk CEO says buyers of $49 compounded Wegovy pill will be 'wasting' their money</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovo Nordisk CEO says buyers of $49 compounded Wegovy pill will be 'wasting' their money\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-05 22:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a> CEO says buyers of $49 compounded Wegovy pill will be 'wasting' their money</title></head><body><p><span>COPENHAGEN, Feb 5 (Reuters)</span><span> - </span>Novo Nordisk <span>NOVOb.CO</span> CEO Mike Doustdar on Thursday told analysts in a call that people taking a compounded copy of the drugmaker's Wegovy pill priced at $49 will be wasting their money as the compound will not be absorbed in their body. </p><p> (Reporting by Maggie Fick and Louise Rasmussen, editing by Terje Solsvik)</p><p> ((Louisebreusch.rasmussen@tr.com; +45 21 27 97 79;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVO","symbol_name":"诺和诺德","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260205:nS8N3YA00Y:1","article_id":"2609301536","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2609301536","pubTimestamp":1770301898,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Novo Nordisk CEO says buyers of $49 compounded Wegovy pill will be 'wasting' their moneyCOPENHAGEN, Feb 5 (Reuters) - Novo Nordisk NOVOb.CO CEO Mike Doustdar on Thursday told analysts in a call that p","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NVO":"诺和诺德","BK4196":"保健护理服务"},"translate_title":"诺和诺德首席执行官表示，购买49美元复合Wegovy药丸的买家将“浪费”他们的钱","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVO":1.95},"content_text":"Novo Nordisk CEO says buyers of $49 compounded Wegovy pill will be 'wasting' their moneyCOPENHAGEN, Feb 5 (Reuters) - Novo Nordisk NOVOb.CO CEO Mike Doustdar on Thursday told analysts in a call that people taking a compounded copy of the drugmaker's Wegovy pill priced at $49 will be wasting their money as the compound will not be absorbed in their body.  (Reporting by Maggie Fick and Louise Rasmussen, editing by Terje Solsvik) ((Louisebreusch.rasmussen@tr.com; +45 21 27 97 79;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}